Discovery of oxindole-based FLT3 inhibitors as a promising therapeutic lead for acute myeloid leukemia carrying the oncogenic ITD mutation.
Bender O, Shoman ME, Ali TFS, Dogan R, Celik I, Mollica A, Hamed MIA, Aly OM, Alamri A, Alanazi J, Ahemad N, Gan SH, Malik JA, Anwar S, Atalay A, Beshr EAM.
Bender O, et al. Among authors: aly om.
Arch Pharm (Weinheim). 2023 Feb;356(2):e2200407. doi: 10.1002/ardp.202200407. Epub 2022 Nov 20.
Arch Pharm (Weinheim). 2023.
PMID: 36403191